88% of Americans want Medicare to negotiate prescription drug prices. The Inflation Reduction Act made this possible in 2024 — and produced price cuts of 38-79% on the first 10 drugs. Now that program faces rollback. In competitive 2026 districts, the personal math of drug costs is one of the most powerful campaign issues available to Democrats.
- The IRA's 2024 first negotiation round achieved price reductions of 38-79% on 10 high-cost Medicare drugs (including Eliquis, Jardiance, Xarelto, Januvia) — the first successful direct Medicare drug price negotiations in the program's history.
- Drug price negotiation polls at 79-83% overall support across all partisan groups — one of the highest approval ratings of any specific healthcare policy tested, making it a uniquely powerful issue for Democratic candidates in competitive races.
- The political vulnerability for Republicans in 2026 is precise: any reconciliation provision reducing negotiation scope, delaying timelines, or limiting savings to beneficiaries becomes immediately translatable into a "gave your drug savings back to Big Pharma" attack message.
- PhRMA's sustained anti-negotiation advertising campaign since 2022 has failed to move public opinion — drug negotiation support has remained stable despite years of industry-funded messaging, an unusual failure rate for sustained political advertising.
- Senior voters (65+) are the direct beneficiaries and the highest-turnout midterm age group, making drug pricing one of the highest-stakes issues in the 2026 senior voter mobilization calculus for both parties.
The Policy Behind the Numbers
The Inflation Reduction Act's drug pricing provisions were the first time in Medicare's history that the program was allowed to negotiate prices directly with pharmaceutical companies. The first round of negotiations in 2024 covered 10 drugs with high Medicare spending — including Eliquis, Jardiance, Xarelto, Januvia, and Farxiga. The price reductions achieved ranged from 38% to 79% below previous list prices. For Medicare beneficiaries, these drugs represent some of the highest out-of-pocket costs in the system.
The insulin cap at $35 per month for Medicare patients has directly benefited approximately 3.7 million beneficiaries who previously paid significantly more. Before the IRA cap, insulin costs varied widely — with some patients paying $300-500 per month. The personal, concrete nature of this savings makes it among the most salient healthcare policy changes in recent memory for affected voters.
Drug Pricing Support by Demographic (2026)
Rollback Threat and the 2026 Stakes
The IRA drug pricing provisions face multiple challenges in 2026. The Trump administration has signaled interest in limiting the negotiation program's scope as part of a broader push to reduce pharmaceutical regulatory burden. Congressional Republicans have introduced legislation to restrict the list of eligible drugs. Several pharmaceutical companies are pursuing legal challenges arguing the program constitutes an unconstitutional taking.
For Democrats, this creates a rare opportunity: defending a popular policy that has already delivered concrete savings, against opposition from pharmaceutical companies and a Republican administration. In competitive House and Senate races, particularly in districts with high concentrations of Medicare beneficiaries, the drug pricing contrast is one of the highest-polling issues available. Related: Medicare Prescription Drug Policy 2026.
Frequently Asked Questions
What percentage of Americans support Medicare drug price negotiation?
88% overall — including 94% of Democrats, 89% of independents, and 83% of Republicans. It is one of the highest-polling policy positions in American public opinion and has stayed above 80% for over a decade.
What did the Inflation Reduction Act do for drug pricing?
The IRA authorized Medicare to negotiate prices on 10 high-cost drugs starting in 2024, expanding to 20 in 2026. Negotiated prices came in 38-79% below list price. The $35 insulin cap directly benefits 3.7M Medicare beneficiaries. Both provisions now face rollback threats.
How important is prescription drug pricing as a voting issue in 2026?
It is one of the most politically effective healthcare issues for Democrats in 2026. The combination of 88% bipartisan support, concrete IRA savings already delivered, and the threat of rollback creates a clear contrast — particularly for senior voters who are a high-turnout demographic.
